DDInter364 DDInter636
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin